Literature DB >> 18929609

Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo.

William P Dunworth1, Kimberly L Fritz-Six, Kathleen M Caron.   

Abstract

The lymphatic vascular system functions to maintain fluid homeostasis by removing fluid from the interstitial space and returning it to venous circulation. This process is dependent upon the maintenance and modulation of a semi-permeable barrier between lymphatic endothelial cells of the lymphatic capillaries. However, our understanding of the lymphatic endothelial barrier and the molecular mechanisms that govern its function remains limited. Adrenomedullin (AM) is a 52 amino acid secreted peptide which has a wide range of effects on cardiovascular physiology and is required for the normal development of the lymphatic vascular system. Here, we report that AM can also modulate lymphatic permeability in cultured dermal microlymphatic endothelial cells (HMVEC-dLy). AM stimulation caused a reorganization of the tight junction protein ZO-1 and the adherens protein VE-cadherin at the plasma membrane, effectively tightening the endothelial barrier. Stabilization of the lymphatic endothelial barrier by AM occurred independently of changes in junctional protein gene expression and AM(-/-) endothelial cells showed no differences in the gene expression of junctional proteins compared to wildtype endothelial cells. Nevertheless, local administration of AM in the mouse tail decreased the rate of lymph uptake from the interstitial space into the lymphatic capillaries. Together, these data reveal a previously unrecognized role for AM in controlling lymphatic endothelial permeability and lymphatic flow through reorganization of junctional proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929609      PMCID: PMC2639781          DOI: 10.1016/j.peptides.2008.09.009

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  32 in total

1.  Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor.

Authors:  Tatiana V Petrova; Taija Mäkinen; Tomi P Mäkelä; Janna Saarela; Ismo Virtanen; Robert E Ferrell; David N Finegold; Dontscho Kerjaschki; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

2.  Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage.

Authors:  Bernhard Brell; Bettina Temmesfeld-Wollbrück; Iris Altzschner; Eckehard Frisch; Bernd Schmeck; Andreas C Hocke; Norbert Suttorp; Stefan Hippenstiel
Journal:  Crit Care Med       Date:  2005-04       Impact factor: 7.598

Review 3.  Development of CGRP antagonists for the treatment of migraine.

Authors:  H Doods
Journal:  Curr Opin Investig Drugs       Date:  2001-09

4.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses.

Authors:  D Q Chu; M Choy; P Foster; T Cao; S D Brain
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function.

Authors:  Kentaro Kajiya; Satoshi Hirakawa; Michael Detmar
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

7.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

8.  Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors.

Authors:  Samantha Fernandez-Sauze; Christine Delfino; Kamel Mabrouk; Christophe Dussert; Olivier Chinot; Pierre-Marie Martin; Francois Grisoli; L'Houcine Ouafik; Françoise Boudouresque
Journal:  Int J Cancer       Date:  2004-03-01       Impact factor: 7.396

9.  Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis.

Authors:  Alexander Yaw Debrah; Sabine Mand; Mohammad Reza Toliat; Yeboah Marfo-Debrekyei; Linda Batsa; Peter Nürnberg; Bernard Lawson; Ohene Adjei; Achim Hoerauf; Kenneth Pfarr
Journal:  Am J Trop Med Hyg       Date:  2007-10       Impact factor: 2.345

10.  Thromboxane modulates endothelial permeability.

Authors:  J M Klausner; S Abu-Abid; J S Alexander; R Hanshke-Mineau; G Goldman; N Morel; C R Valeri; D Shepro; H B Hechtman
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

View more
  33 in total

Review 1.  Dendritic cell interactions with lymphatic endothelium.

Authors:  Erica Russo; Maximilian Nitschké; Cornelia Halin
Journal:  Lymphat Res Biol       Date:  2013-09       Impact factor: 2.589

2.  Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.

Authors:  Christopher Geven; Dirk van Lier; Alice Blet; Roel Peelen; Bas Ten Elzen; Alexandre Mebazaa; Matthijs Kox; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2018-07-03       Impact factor: 4.335

3.  Gastrointestinal lymphatics in health and disease.

Authors:  J S Alexander; Vijay C Ganta; P A Jordan; Marlys H Witte
Journal:  Pathophysiology       Date:  2010-09

4.  Fetal-derived adrenomedullin mediates the innate immune milieu of the placenta.

Authors:  Manyu Li; Nicole M J Schwerbrock; Patricia M Lenhart; Kimberly L Fritz-Six; Mahita Kadmiel; Kathleen S Christine; Daniel M Kraus; Scott T Espenschied; Helen H Willcockson; Christopher P Mack; Kathleen M Caron
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

5.  Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers.

Authors:  M Aslam; U Pfeil; D Gündüz; A Rafiq; W Kummer; H M Piper; T Noll
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

6.  Adrenomedullin Induces Cardiac Lymphangiogenesis After Myocardial Infarction and Regulates Cardiac Edema Via Connexin 43.

Authors:  Claire E Trincot; Wenjing Xu; Hua Zhang; Molly R Kulikauskas; Thomas G Caranasos; Brian C Jensen; Amélie Sabine; Tatiana V Petrova; Kathleen M Caron
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 7.  Relationship between G proteins coupled receptors and tight junctions.

Authors:  Lorenza González-Mariscal; Arturo Raya-Sandino; Laura González-González; Christian Hernández-Guzmán
Journal:  Tissue Barriers       Date:  2018-02-08

8.  Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis.

Authors:  Natalie O Karpinich; Daniel O Kechele; Scott T Espenschied; Helen H Willcockson; Yuri Fedoriw; Kathleen M Caron
Journal:  FASEB J       Date:  2012-10-25       Impact factor: 5.191

9.  Small GTPase Rap1A/B Is Required for Lymphatic Development and Adrenomedullin-Induced Stabilization of Lymphatic Endothelial Junctions.

Authors:  Wenjing Xu; Erika S Wittchen; Samantha L Hoopes; Lucia Stefanini; Keith Burridge; Kathleen M Caron
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 10.  G protein-coupled receptors as potential drug targets for lymphangiogenesis and lymphatic vascular diseases.

Authors:  William P Dunworth; Kathleen M Caron
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-05       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.